Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment‐resistant depression
Human psychopharmacology February 18, 2022 A. P. Jesus-Nunes, G. C. Leal, F. S. Correia-Melo et al. 39 citations
Most people with major depressive disorder do not achieve symptom remission, and treatment-resistant depression is defined by the failure of at least one adequate antidepressant trial. This study investigated clinical predictors of depressive symptom remission and response 24 hours and 7 days after infusions of racemic ketamine and esketamine.